Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
[ad_1] Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who … Read More